Join the conversation

Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Trending Tickers

SMMT logo
Top trending tickerSMMT
$14.14
6.20%
#1
The FDA issued a Complete Response Letter for Summits ivonescimab application in post-TKI EGFR-mutated lung cancer, saying the evidence did not establish a statistically significant overall-survival benefit; traders are reacting to the setback and debating whether it undermines the broader drug thesis. Bearish voices see a major regulatory blow, while bullish traders argue the decision is limited to this indication and are focused on future trials, especially HARMONi-3.
HELP logo
HELP
$8.87
0.11%
#2
Helus Pharmas Phase 3 APPROACH topline readout for HLP003 in major depressive disorder is the dominant focus, with traders treating the results as a high-stakes catalyst. Bullish investors cite the adjunctive design and potential for shorter clinic sessions, while others are wary of disappointing data and dilution; unverified claims about the results remain speculation.
DRTS logo
DRTS
$13.38
0.15%
#3
Positive interim REGAIN data in recurrent glioblastoma is driving attention, with all treated patients alive and objective responses reported in the evaluable group. Traders are enthusiastic about the early results and possible regulatory implications, while some stress that the small sample and response durability still need follow-up.
LUNC logo
LUNC
$0.0000353463
4.63%
#4
A reported rise in trading volume and a price pop have revived interest in LUNC, with bulls pointing to token burns, Binance burn activity and anticipated Market Module 2.0 developments; some also speculate a court outcome could trigger large additional burns, though that remains unconfirmed. Skeptics argue the moves may be short-lived, citing weak liquidity and the tokens large supply.
SPY logo
SPY
$754.37
0.36%
#5
Reports that Jensen Huang may seek a return as Nvidia CEO dominate discussion, with traders speculating that a comeback could lift tech stocks and SPY; others doubt the rumor and warn of volatility. Nvidia earnings and the Anthropic IPO add to the week's focus, alongside debate over whether a recent rebound can hold.
SOL logo
SOL
$72.67
3.55%
#6
Solana is drawing attention amid a broad crypto selloff and a steep decline toward multi-year lows, with traders focused on broken support and further downside risk as Bitcoin weakness weighs on sentiment. Others see the pullback as a buying opportunity and say they are accumulating and staking, leaving the conversation split between capitulation fears and dip-buying.
BB.TSX logo
BB.TSX
$12.69
2.46%
#7
QNXs record royalty-backlog growth and first Alloy Kore design win are driving attention, with traders focused on potential automotive and physical-AI expansion and speculating about further wins. Optimism about the growth opportunity is tempered by debate over how quickly design wins will translate into revenue, alongside concerns about volatility and executive share sales.
FROG logo
FROG
$113.60
2.71%
#8
JFrogs stronger-than-expected quarterly results and raised outlook have fueled a sharp rally and breakout to new highs, with traders highlighting growth in its cloud business and AI-related demand. The mood is broadly bullish on the momentum, though some see the stock as overvalued or extended and are waiting for a pullback.
CAPR logo
CAPR
$9.53
6.93%
#9
Attention is centered on the FDAs November 22 decision date for Capricors deramiocel application for Duchenne muscular dystrophy, with traders debating whether the evidence supports approval for the upper-limb indication or whether the FDA may issue a rejection or delay. Bulls point to HOPE-3 results and anticipate a short squeeze, while skeptics highlight FDA concerns about the trial analysis and warn of sharp downside in this binary event.
XRP logo
XRP
$0.9745
6.74%
#10
XRPs steep decline amid a broader crypto selloff, with traders pointing to Bitcoin weakness and leveraged liquidations, is driving attention. Some see the rebound as a buying opportunity, while others doubt it will last and expect further downside.

About Stocktwits

With over 10 million users, Stocktwits helps you tap into the real-time sentiment and trending insights across stocks, ETFs, and crypto.